PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsAdvance in RNA therapy technique

BioNews

Advance in RNA therapy technique

Published 9 June 2009 posted in News and appears in BioNews 427

Author

Stuart Scott

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

RNA interference (RNAi), a genetic therapy with huge therapeutic potential across medicine, is back on track after a paper published in Nature this week. Research into the technique - which has garnered a Nobel prize and swathes of excitable column inches - suffered a setback last year when a...

RNA interference (RNAi), a gene therapy with huge therapeutic potential across medicine, is back on track after a paper published in Nature this week. Research into the technique - which has garnered a Nobel prize and swathes of excitable column inches - suffered a setback last year when a group at Stanford University showed that the it was lethal to mice. The new research, performed at the Massachusetts Institute of Technology (MIT), has circumnavigated the problem by simplifying the process.


RNAi, which occurs normally in plants and animals, allows a gene to be specifically 'silenced'. Our genome operates by sending instructions from DNA in the form of mRNA (messenger RNA) for the manufacture of proteins. When RNAi occurs, tiny sections of short interfering RNA (siRNA) in complex with other proteins, bind to a gene's mRNA and destroy it before a protein can be produced.


The technique is standard practise on cultured cell lines in many research labs, with little or no ill-effects to cells - other than those intended. The problem lies in transmission of the siRNA molecules into the cells of living organisms. Currently, RNAi relies on modified viruses to export a gene called short hairpin RNA (shRNA), a precursor of siRNA, into cells. Once in the cell the gene manufactures shRNA and then uses cellular machinery to break itself down into siRNA, which can get to work nullifying its target mRNA.


The commandeering of the cell's machinery to cleave shRNA into siRNA, however, disrupts another critical intracellular system called the microRNA pathway, responsible for blocking RNA, leading to toxicity in mice.


Instead of using a virus-based delivery, MIT scientists have added the siRNA directly to cellular fluid, achieving 80 per cent silencing of target genes in the process. 'Using chemically synthesized siRNA, you can deliver sufficient siRNA to achieve therapeutically valuable gene silencing, without interfering with the cell's endogenous microRNA', said David Bumcrot, a director of research at Alnylam (an MIT startup) and one of the authors of the paper.


'We wanted to demonstrate that if you go downstream of that (export) step in the pathway, you don't get interference with the microRNA pathway', continued Bumcrot. 'With synthetic siRNAs, we deliver a defined dose and we know how long the effect lasts. If toxicity issues arise, dosing can be stopped at any time. It's much easier to control and, therefore, safer'. Details of the new technique will be published in another forthcoming coming paper.

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
15 July 2013 • 2 minutes read

Drug found effective in 'silencing' disease gene

by Matthew Thomas

A drug has been found to suppress the gene underlying a rare but fatal disease, according to results from an early-stage clinical trial...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Treatment hope for childhood muscle wasting disorder

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
13 June 2022 • 2 minutes read

Drop in diversity of blood stem cells leads to old-age health issues

5 July 2022 • 1 minute read

No difference between fresh and frozen sperm for IUI

4 July 2022 • 2 minutes read

Shorter IVF protocol reduces risk of OHSS

4 July 2022 • 2 minutes read

USA scrambles to understand implications of Roe v Wade on fertility industry

4 July 2022 • 2 minutes read

Genetic and epigenetic causes of IVF embryo arrest discovered

4 July 2022 • 2 minutes read

Dutch donor-conceived people seek answers

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856